SCHEMBL4475484

SCHEMBL4475484

CN1CCN(Cc2ccc(-c3ccccc3Cl)cc2)C[C@@H]1Cc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.54
GRM2 Q14416 1/20 0.45
SIGMAR1 Q99720 1/20 0.44
CHKA P35790 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4475494 1.00 CNR2 (0.54) CNR2GRM2SIGMAR1CHKA
SCHEMBL4484372 0.92 CNR2 (0.56) CNR2SIGMAR1CHKA
SCHEMBL4484381 0.92 CNR2 (0.56) CNR2SIGMAR1CHKA
SCHEMBL4649627 0.88 SIGMAR1 (0.45) CNR2SIGMAR1CHKA
SCHEMBL4461953 0.88 CNR2 (0.59) CNR2SIGMAR1
SCHEMBL4476140 0.86 CNR2 (0.52) CNR2SIGMAR1
SCHEMBL4486819 0.86 CNR2 (0.52) CNR2SIGMAR1
SCHEMBL4476137 0.86 CNR2 (0.52) CNR2SIGMAR1
SCHEMBL4465004 0.84 CNR2 (0.59) CNR2
SCHEMBL4465011 0.84 CNR2 (0.59) CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
EP-1966132-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-09-10 EP disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, ARRB1 CNR2 2/4885GRM2 219/4885SIGMAR1 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.